12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALD-401: Phase II start

This quarter, Aldagen will begin a U.S. Phase II trial to evaluate ALD-401 given on days 13-19 post-stroke...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >